Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.

ABSTRACT:

Objective

It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression.

Methods

We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively.

Results

There were no significant differences between QUEXR300 a

SUBMITTER: Kishi T 

PROVIDER: S-EPMC7292317 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature